Ezetimibe in chronic kidney disease: an effect on the risk of developing cardiovascular and cerebral complications


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the effectiveness and safety of lipid-lowering therapy in patients with cardiovascular and renal diseases. attention is focused on an inhibitor of cholesterol absorption in the small intestine - ezetimibe. Data on the hypolipidemic and anti-inflammatory effects of ezetimibe and its combination with statins are summarized. Ezetimibe has been shown to have a good safety profile, significantly reducing cardiovascular and cerebral risk, as well as the progression of chronic kidney disease.

Full Text

Restricted Access

About the authors

Ilkhom T. Murkamilov

Kyrgyz State Medical Academy named after I.K. Akhunbaev; Kyrgyz-Russian Slavic University

Email: murkamilov.i@mail.ru
PhD in Medical Sciences, Nephrologist, Deputy Associate Professor at the Department of Faculty Therapy; Senior Lecturer of the Department of Therapy № 2in the specialty "General Medicine Bishkek, Kyrgyzstan

L. S Sabirov

Kyrgyz Russian slavic university

Email: sabirov_is@mail.ru
Doctor of Medical Science, Professor, Head of the Department of Therapy № 2 in the Specialty "Medical Care" Bishkek, Kyrgyzstan

Viktor V. Fomin

FSAEI he First Moscow State Medical University named after I.M. Sechenov

Email: fomin_vic@mail.ru
Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Faculty Therapy № 1, ViceRector for Clinical Work and Postgraduate Professional Education Moscow, Russia

Zhamila A. Murkamilova

Kyrgyz Russian slavic university

Email: murkamilovazh.t@mail.ru
Correspondence Post-Graduate Student at the Department ofTherapy № 2 in the specialty "General Medicine" Bishkek, Kyrgyzstan

Furkat A. Yusupov

Osh State University

Email: furcat_y@mail.ru
Doctor of Medical Sciences, Professor, Head of the Department of Neurology, Neurosurgery and Psychiatry, Faculty of Medicine; Chief Neurologist of the Southern Region of Kyrgyzstan Osh, Kyrgyzstan

Nodira A. Redzhapova

Osh State University

Email: nredzhapova@mail.ru
Postgraduate Student at the Department of Neurology and Psychiatry, Faculty of Medicine Osh, Kyrgyzstan

Zafarbek R. Rayimzhanov

Kyrgyz State Medical Academy named after I.K. Akhunbaev

Email: rzrmam@mail.ru
correspondence graduate student Bishkek, Kyrgyzstan

References

  1. Моисеев В.С., Мухин Н.А., Смирнов А.В. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Рос. кардиологический журнал. 2014;(8):7-37
  2. Bikbov B., Purcell C.A., Levey A.S., et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-33. https://dx.doi.org/10.1016/S0140-6736(20)30045-3
  3. Cockwell P., Fisher L.A. The global burden of chronic kidney disease. Lancet. 2020;395(10225):662-4. https://dx.doi.org/10.1016/S0140-6736(19)32977-0
  4. Ellis P. The global burden of kidney disease. J. Kidney Care. 2020;5(2):102. https://dx.doi.org/10.12968/jokc.2020.5.2.102
  5. Катапано А., Шляхто Е.В., Мартынов А.И. и др. Консенсус совета экспертов роль комбинированной гиполипидемической терапии (симвастатин/эзетимиб 20/10 мг) в коррекции нарушений липидного обмена у больных хронической болезнью почек. Кардиоваскулярная терапия и профилактика. 2013;12(4):75-8.
  6. Angeli F., Reboldi G, Verdecchia P. Blood pressure variability and risk of stroke in chronic kidney disease. J. Hypertension. 2020;38(4):599-602. https:// dx.doi.org/10.1097/HJH.0000000000002339
  7. Смирнов А.В. Дислипопротеидемии и проблемы нефропротекции. Нефрология. 2002;6(2):8-14.
  8. Колина И.Б., Ставровская Е.В. Эффективность и безопасность гиполипидемической терапии при хронической болезни почек. Тер. архив. 2013;6(85):73-7.
  9. Reule S., Ishani A., Goldsmith D. Dyslipidemia and Chronic Kidney Disease. Chronic Renal Disease. Acad. Press. 2020.1093-101. https://doi.org/10.1016/ B978-0-12-815876-0.00066-8.
  10. Мельник А.А. Нарушение липидного обмена и его коррекция при хронической болезни почек. Почки. 2016;2(16):85-95.
  11. Барбараш О.Л., Зыков М.В., Кашталап В.В., Барбараш Л.С. Распространенность и клиническая значимость мультифокального атеросклероза у пациентов с ишемической болезнью сердца. Кардиология. 2011;51(8):66-71
  12. Рекомендации Европейского общества кардиологов/Европейского обществаатеросклероза 2019 г. по диагностике и лечению нарушений липидного обмена: коррекциялипидного профиля для снижения сердечно-сосудистого риска (краткая версия). Терапия. 2019;8:14-51
  13. Sniderman A.D., Thanassoulis G., Glavinovic T., et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA. Cardiology. 2019;4(12):1287-95. https://doi.org/10.1001/jamacardio.2019.3780
  14. Кобалава Ж.Д., Гуревич В.С., Галявич А.С. и др. Возможности клинического применения препарата эзетимиба Отрио (АО «АКРИХИН», Россия) у пациентов высокого и очень высокого сердечно-сосудистого риска, не достигших целевых значений показателей липидного обмена. Заключение Совета экспертов. Кардиология. 2019;59(5):47-57.
  15. Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 2020;41(1):111-88. https://doi.org/10.1093/eurheartj/ehz455
  16. Шапошник И.И., Генкель В.В. Возможности достижения целевых уровней липидов с помощью комбинированной терапии статинами и эзетимибом. Consilium Medicum. 2019;21(5):38-42.
  17. Rosenblum S.B., Huynh T., Afonso A., et al. Discovery of 1-(4-fluorophenyl)-(3 R)-[3-(4-fluorophenyl)-(3 S)-hydroxypropyl]-(4 S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 1998;41(6):973-80. https://doi. org/10.1021/jm970701f
  18. Эзетимиб (Ezetimibe). https://www.rlsnet.ru/mnn_index_id_3288.htm
  19. Лякишев А. А., Семенова А.Е., Миклишанская С. В., Кухарчу к В.В. Перспективы применения эзетимиба в кардиологической практике. Кардиоваскулярная терапия и профилактика. 2010;9(7):86-9.
  20. Ge L., Wang J., Qi W., et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell. Metab. 2008;7(6):508-19. https://doi.org/10.1016/jxmet.2008.04.001
  21. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92. https://doi.org/10.1016/S0140-6736(11)60739-3
  22. Гуревич В.С. Место эзетимиба в оптимальной гиполипидемической терапии: согласованные позиции и дискуссионные вопросы. РМЖ. Медицинское обозрение. 2019;6:11-6.
  23. Leiter L.A., Betteridge D.J., Farnier M., et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabet. Obes. Metabol. 2011;13(7):615-28. https://doi.org/10.1111/ j.1463-1326.2011.01383.x
  24. Сумароков А.Б., Кухарчук В.В. Гиполипидемические и плейотропные эффекты комбинации симвастатина и эзетимиба у больных различными видами гиперлипидемий. Тер. архив.2014;86(12):107-15.
  25. Sudhop T., von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs. 2002;62(16):2333-47. https://doi. org/10.2165/00003495-200262160-00002
  26. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Национальные рекомендации, V пересмотр. Кардиоваскулярная терапия и профилактика. 2012;11(4). Приложение 1.
  27. Pandey A.S., Bissonette S., Boukas S., et al. Effectiveness and tolerability of ezetimibe co-administrated with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial, Arch. Med. Sci. 2011;5:767-75. https://doi.org/10.5114/aoms.2011.25550
  28. Kerzner B., Corbelli J., Sharp S., et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 2003;91(4):418-24. https://doi.org/10.1016/S0002-9149(02)03236-8
  29. Gagne C., Bays H.E., Weiss S.R., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 2002;90(10):1084-91. https://doi. org/10.1016/S0002-9149(02)02774-1
  30. Al-Falahi Z, Williamson J., Dimitri H. Atrial Fibrillation and Sleep Apnoea: Guilt by Association? Heart, Lung and Circulation. 2017;26(9):902-10. https://doi.org/10.1016/j.hlc.2017.05.127
  31. Ambegaonkar B.M., Tipping D., Polis A.B., et al. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis. 2014;237(2):829-37. https:// doi.org/10.1016/j.atherosclerosis.2014.10.105
  32. Sawada S.S., Lee I.-M., Naito H., et al. Cardiorespiratory fitness, body mass index, and cancer mortality: a cohort study of Japanese men. BMC. Public Health. 2014;14(1):1012. https://doi.org/10.1186/1471-2458-14-1012
  33. Wanner C., Tonelli M. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Internat. 2014;85(6):1303-309. https://doi. org/10.1038/ki.2014.31
  34. Rossebo A.B., Pedersen T.R. Allen С., et al. Desigh and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. Am. J. Cardiol. 2007;99:970-73.
  35. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015;372:2387-97. https://doi.org/10.1056/NEJMoa1410489
  36. Айтбаев К.А., Муркамилов И.Т., Фомин В.В. Гиполипидемическая терапия при хронической болезни почек: влияние на риск развития сердечно-сосудистых заболеваний и дисфункцию почек. Кардиология. 2019;59(2):79-87.
  37. Ahmad F, Leake D.S. Lysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages. J. Lipid Res. 2019;60(1):98-110. https://www.jlr.org/ content/60/1/98.full.pdf+html
  38. Moutsouri E., Liberopoulos E., Tellis C., et al. Comparison of the effect of simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 2013;231:8-14. https://doi.org/10.1016/j.atherosclerosis.2013.08.013
  39. Kalogirou M., Tsimihodimos V., Saougos V., et al. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pretreatment. Arch. Med. Sci. 2007;3(4):344-50
  40. Liberale L., Carbone F., Montecucco F., Sahebkar A. Statins reduce vascular inflammation in atherogenesis: a review of underlying molecular mechanisms. Int. J. Biochem. Cell. Biol. 2020; 105735. https://doi.org/10.1016/j. biocel.2020.105735
  41. Thompson G., Davison G.W., Crawford J., Hughes C.M. Exercise and inflammation in coronary artery disease: A systematic review and meta-analysis of randomised trials. J. Sports Sci. 2020;1-13. https://doi.org/10.1080/02640 414.2020.1735684
  42. Милютина О.В., Чичерина Е.Н. Прогностическая роль С-реактивного белка в развитии риска кардиальных событий. Рос. кардиол. журн. 2011;(1):71-3.
  43. Хадарцев А.А., Логаткина А.В., Терехов И.В., Бондарь С.С. Динамика проявлений метаболического синдрома у пациентов с артериальной гипертензией на фоне комплексного использования низкоинтенсивной микроволновой терапии. Артериальная гипертензия. 2018;24(2):206-16.
  44. Krysiak R., Zmuda W., Okopien B. The Effects of ezetimibe, administrered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J. Intern. Med. 2012;271:32-42.
  45. Kater A.L.A., Batista M.C., Ferreira S. Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol. Metabol. Syndrome. 2010;2(1):34-41.
  46. Fleg J., Mete M., Howard B.V., et al. Effects of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes. The SANDS (STOP Atherosclerosis in Native Diabetics Study) Trial. JACC. 2008;52:2198-205.
  47. Otani T., Iwasaki M., Sasazuki S., et al. Japan Public Health Center-Based Prospective Study Group. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol. Prev. Biomark. 2006;15(4):690-95. https://doi.org/10.1158/1055-9965.
  48. Tie C., Gao K., Zhang N., et al. Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. PLOS ONE. 2015;10(11):e0142430. https://doi.org/ 10.1371/journal.pone.0142430
  49. Шапошник И.И., Генкель В.В. Плейотропные эффекты эзетимиба. Кардиология. 2019;59(12):12-7.
  50. Dolezelova E., Stein E., Derosa G., et al. Effect of ezetimibe on plasma adipokines: a systematic review and metaanalysis. Br. J. Clin. Pharmacol. 2017;83(7):1380-96. https://doi.org/10.1111/bcp.13250
  51. Mihaylova B., Kent S., Herrington W., et al. Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease. Kidney Int. 2019;96:1. https://doi.org/10.1016/j.kint.2019.01.028
  52. Um J.Y., Kim H.M. Frequencies of the tumor necrosis factor gene polymorphisms in the Korean population. Hereditas. 2003;139:184-88. https:// doi.org/10.1111/j.1601-5223.2003.01741.x
  53. Raj D.S., Pecoits-Filho R., Kimmel P.L. Inflammation in chronic kidney disease. Chronic Renal Disease. Acad. Press. 2020;355-73. https://doi. org/10.1016/B978-0-12-815876-0.00024-3.
  54. Sugiyama S., Jinnouchi H., Hieshima K., et al. A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus. Lipids in Health and Disease. 2015;14(1):37. https://doi.org/10.1186/s12944-015-0028-z
  55. Kurobe H., Aihara K., Higashida M., et al. Ezetimibe Monotherapy Ameliorates Vascular Function in Patients with Hypercholesterolemia Through Decreasing Oxidative Stress. J. Atheroscler. Thromb. 2011;18(12):1080-89. https://doi. org/10.5551/jat.9548
  56. Qin J., Wang L., Liu Z, et al. Ezetimibe Protects Endothelial Cells against Oxidative Stress through Akt/GSK-3fi Pathway. Current. Med. Sci. 2018;38(3):398-404. https://doi.org/10.1007/s11596-018- 1892-3
  57. Chen C.H., Cheng C.Y., Chen Y.C., et al. Rosuvastatin inhibits pressure -induced fibrotic responses via the expression regulation of prostacyclin and prostaglandin E2 in rat renal tubular cells. Eur. J. Pharmacol. 2013;700(1-3):65-73. https://doi.org/10.1016/j.ejphar.2012.12.017
  58. Takase H., Dohi Y., Okado T., et al. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur. J. Clin. Invest. 2012;42(12):1287-94. https://doi.org/10.1111/eci.12000
  59. Koh K.K., Oh P.C., Sakuma I., et al. Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia. Int. J. Cardiol. 2015;199:126-31. https://doi.org/10.1016/j.ijcard.2015.07.016
  60. Ohbu-Murayama K., Adachi H., Hirai Y., et al. Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome. J. Diabet. Invest. 2015;6(3):325-33. https://doi.org/10.1111/jdi.12298
  61. Wu H., Shang H., Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2018;60(2):229-39. https://doi.org/10.1007/s12020-018-1541-4
  62. Kashani A., Sallam T., Bheemreddy S., et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am. J. Cardiol 2008;101(11):1606-13. https://doi.org/10.1016//. amjcard.2008.01.041
  63. Luo L., Yuan X., Huang W., et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Intern. Med. J. 2015;45(5):546-57. https://doi.org/ 10.1111/imj.12706
  64. Liu Z., Hao H., Yin C., et al. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget. 2017;8(25):41582-9. https://doi. org/10.18632/oncotarget.15078
  65. Lloyd-Jones D.M., Morris P.B., Ballantyne C.M., et al. 2017Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapiesfor LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J. Am. Coll. Cardiol. 2017;70(14):1785-822. https://doi.org/10.1016/j.jacc.2017.07.745

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies